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Background and Aim: The metabolic syndrome (MetS) is a pathological condition comprised of
abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. It has become a major threat
globally, resulting in rapidly increasing rates of diabetes, coronary heart disease, and stroke. The
polyphenol resveratrol (RES) is believed to improve glucose homeostasis and insulin resistance by
activating sirtuin, which acetylates and coactivates downstream targets and affects glucose and lipid
homeostasis in the liver, insulin secretion in the pancreas, and glucose uptake in skeletal muscle. We
studied the effects of RES on insulin resistance, glucose homeostasis, and concomitant effects on
adipose tissue metabolism and fecal microbiota in insulin-resistant subjects with the MetS.
Methods: A total of 28 obese men with the MetS were studied during a 35-day stay in the Rockefeller
University Hospital metabolic unit. Subjects were randomized to receive RES 1 g orally twice
daily or placebo while kept weight stable and consuming a western-style diet. At baseline, and after
30 days of RES or placebo administration, subjects underwent testing that included a euglycemic,
hyperinsulinemic clamp, 2-h oral glucose tolerance test (GTT), resting energy expenditure, daily
blood pressure monitoring, abdominal adipose tissue biopsy, and fecal and blood collections.
Results: RES induced no changes in insulin resistance but reduced the 120-min time point and the area
under the curve for glucose concentration in the 2-h GTT. In post-hoc analysis, Caucasian subjects showed a
significant improvement in insulin sensitivity and glucose homeostasis after GTT, whereas non-Caucasians
showed no similar effects. Levels of fasting plasma RES and its primary metabolite dihydroresveratrol
were variable and did not explain the racial differences in glucose homeostasis. RES administration to
Caucasian subjects leads to an increase in several taxa including Akkermansia muciniphila.
Conclusions: RES 2 g administered orally to obese men with MetS and insulin resistance marginally
altered glucose homeostasis. However, in a small group of Caucasians, insulin resistance and glucose
homeostasis improved. No concomitant changes in adipose tissue metabolism occurred, but fecal
microbiota showed RES-induced changes.
Relevance for Patients: The MetS increases the risk of diabetes, heart disease, and stroke.
A major component of the syndrome is insulin resistance, resulting in systemic inflammation and
hyperinsulinemia. The primary treatment consists of lifestyle changes, improved diet, and increased
physical activity. This is often unsuccessful. In this study, RES was well tolerated. In Caucasian men,
it significantly improved insulin sensitivity and glucose homeostasis. Similar results were found in
studies that consisted exclusively of Caucasian men. However, RES presents a novel addition to the
current treatment of the MetS and its sequelae.
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1. Introduction
The metabolic syndrome (MetS) is defined by central obesity,
pre-diabetes, insulin resistance, lipid disorders, and hypertension.
MetS is associated with an increased risk for cardiovascular
disease, diabetes, and cancer [1]. About one-third of the adult U.S.
population has the MetS, and prevalence increases with age [2,3].
Compared to adults 20–39 years of age, those 40–59 years of age
were 3 times as likely, and those over the age of 60 were 6 times
as likely to have MetS [3]. With aging of the population, the
incidence of this condition is expected to rise markedly.
Insulin resistance is a central component of the MetS and is
associated with obesity in which the hormone signaling cascade is
diminished in adipose tissue and skeletal muscle. The liver fails to
decrease glucose production in the presence of hyperglycemia, and
lipid stores are released from adipose tissue. This reduction in insulin
action results in increased inflammation which contributes further
to the insulin resistance [4]. Insulin resistance sets the stage for
progression to diabetes by increasing the demand on pancreatic beta
cells to produce insulin, eventually exhausting the insulin supply.
In this study, we examine the effects of trans-resveratrol (RES)
(3,5,4’-trihydroxy-trans-stilbene), a natural product extracted from
Japanese knotweed [5], peanuts, grapes, and certain berries [6],
on insulin resistance in obese men with the MetS. RES dietary
intake is very low, estimated to be only about 100 µg/day from
dietary intake [7]. RES can act as a polyphenolic sirtuin (SIRT1)
activator to acetylate and activate or deactivate many substrates,
including Forkhead transcription factor and peroxisome
proliferator-activated receptor-y by transactivating the coactivator
proliferator-activated receptor-γ coactivator 1α (PGC-1α) [8]. This
is accompanied by effects on both glucose and lipid metabolism.
SIRT1 is expressed highly in many tissues including muscle,
pancreas, and adipose tissues. Thus, RES, as a natural activator of
SIRT1, has the capacity to greatly affect nutrient metabolism. Fat
deposition can be inhibited and pancreatic β cells protected from
cytokine-induced damage [9]. Specifically, RES has been reported
to improve glucose tolerance and insulin resistance in rodents [10]
and humans [11]. In patients with cardiovascular disease, RES
has been reported to reduce inflammation, as demonstrated by
decreased circulating inflammatory markers such as C-reactive
protein, interleukin 1 (IL-1), and IL-6 [12]. In humans, RES
was also found to significantly suppress postprandial glucagon
responses [13], contributing to improved insulin sensitivity. In
a meta-analysis evaluating 11 studies involving 388 diabetic
subjects, Liu et al. [14] found that RES significantly reduced
fasting glucose, insulin, hemoglobin A1C, and insulin resistance
as measured by the homeostatic model assessment (HOMA).
In patients with cancer, RES decreased oxidative stress and
inflammation, through targeting of TANK-binding kinase 1,
which is activated in many chronic inflammatory diseases [15].
RES can be modified by microbiota principally present in
the colon, leading to the transformation of several metabolic
products [16]. Furthermore, in mice, RES can alter the gut
microbiota with important metabolic effects, including reducing
fat stores, thereby decreasing obesity [17]. RES also can alter
Distributed under creative commons license 4.0

the formation of trimethylamine-N-oxide (TMAO), through
remodeling of the microbiota and inhibition of bile acid synthesis.
This reduction of TMAO by RES may decrease the development
of atherosclerosis and coronary heart disease [18]. RES
administration has been accompanied by changes in subcutaneous
and visceral adipose tissues in rodents [19,20].
The primary hypothesis of our study was to determine if high
dose RES, administered to obese men with insulin resistance and
the MetS, would improve insulin sensitivity, glucose tolerance,
and other features of the MetS and thus possibly contribute
to established therapies of the disease. Secondary aims were
to determine whether RES-induced changes in the MetS were
accompanied by concomitant changes in gene expression of
adipose tissue and on gut microbiota, as determined in the feces.
Previous clinical trials of RES have shown improvement in
one of the components of the MetS as discussed above. To our
knowledge, this is the first human study to determine the effects
of the RES on obese men with the MetS, under stable metabolic
conditions in a randomized, placebo-controlled trial.

2. Materials and Methods
2.1 Subjects
Subjects were recruited from the surrounding community
through advertisements in local newspapers and online and from
the Rockefeller University subject repository. Eligible subjects
were obese men (body mass index [BMI] 30–40 kg/cm2) with
insulin resistance determined by euglycemic, hyperinsulinemic
clamp (i.e., M ≤ 6.5 mg/kg/min), between the ages of 30–70 years,
and three other features of the MetS. These features included
fasting blood glucose ≥100 mg/dl, serum triglycerides >150
<500 mg/dl, high-density lipoprotein cholesterol ≤40 mg/dl, waist
circumference ≥102 cm, and blood pressure ≥l30 mmHg systolic
or ≥85 mmHg diastolic without medication, using the National
Cholesterol Education Program American College of Physicians
III 2005 criteria [21]. Exclusions were current smokers and
subjects taking statins and medications metabolized by cytochrome
p450 3A, elevated liver enzymes, diabetes (fasting blood glucose
>125 mg/dl or hemoglobin A1C > 6.5%, or current diagnosis of
diabetes), HIV infection, or abnormal thyroid function. Subjects
gave a written informed consent using good clinical practice
guidelines. The study was approved by the Institutional Review
Board and the Advisory Committee for Clinical and Translational
Science at The Rockefeller University (Protocol JWA-0786) and
was registered with Clinical Trials.gov. # NCT01714102.
Sixty-one subjects were screened; 31 met the enrollment criteria
and were randomized 1:1 by the research pharmacist before entering
the study (Figure 1). Due to the complexity and time required of
the clamp procedure, the baseline clamp was performed as the
final screen of the study, with subjects in the hospital to have it
performed. Subjects understood, before enrolling, that they might
be disqualified based on the result of the clamp. Withdrawn was
one subject who left due to housing problems, one was withdrawn
due to poor venous access, and one left due to unrelated illness.
The remaining 28 subjects completed the 35-day study, 14
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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Enrollment

Assessed for eligibility (n=61)
Excluded (n=30)
• Not meeting inclusion criteria (n=26)
• Declined to participate (n=4)

Randomized (n=31)

Allocaon
Allocated to intervention (n=15) Resveratrol
• Did not receive allocated intervention
(n=1)

Allocated to intervention (n=16) Placebo
• Did not receive allocated intervention (n=1)
1 subject left early due to housing problems

•

1 withdrawn due to poor venous access

Received allocated intervention (n=15)

•

Received allocated intervention (n=14)

Follow -Up
Lost to follow-up (n=0)

Lost to follow-up (n=0)

Discontinued intervention (n=0)

Discontinued intervention due to acute,
unrelated, illness (n=1)

Analysis
Analyzed (n=14)
• Excluded from analysis (n=0)

Analyzed (n=14)
Excluded from analysis (n=0)

•

Figure 1: Trend flow chart.

randomly assigned to each group (Figure 1). Eleven subjects were
Caucasian and 17 were non-Caucasian (13 African Americans, 3
Afro-Latinos, and 1 African American/Asian). This single-center
study was performed at The Rockefeller University Hospital
(RUH) between October 2012 and September 2015.
2.2 Design and Setting
This was a double-blind pilot randomized parallel group design
placebo-controlled study. Subjects initially were screened in the
Outpatient Research Center at the RUH, where they met with the
study principal investigator J.W. Screening procedures comprised
of a complete history and physical examination, fasting blood
testing, resting energy expenditure (REE), and waist measurements.
Eligible subjects were randomized by the research pharmacist
in a 1:1 ratio using a web-based randomization program, to receive
either RES or placebo. The study team and subjects were blinded
as to the randomization to avoid bias. Subjects were admitted to the
Rockefeller University inpatient metabolic unit for 35 days. They
were fed for 4 days with an isocaloric western-style diet, (50%
carbohydrate, 15% protein, 35% fat consisting of 13% saturated
fat, 13% monosaturated fat, and 7% polyunsaturated fat) [22].
Calories required to keep weight stable were determined by the
REE data, a 3 days’ food diary, and subject’s reported activity
level. Developed by the Bionutrition Department, the diet included
Distributed under creative commons license 4.0

minimal amounts of RES-containing foods. On day 4, insulin
sensitivity was measured by the euglycemic hyperinsulinemic
clamp procedure. Insulin-resistant subjects (defined as
M ≤ 6.5 mg/kg/min) completed the remaining baseline testing,
which included blood tests (complete blood count, electrolytes,
liver function tests, blood urea nitrogen, creatinine, and C-reactive
protein), 75 g, 2-h oral glucose tolerance test (GTT), REE, waist
measurement, daily BP monitoring, abdominal subcutaneous
adipose tissue aspiration biopsy, fecal collection, and serum
collection for insulin and lipids.
After baseline testing, subjects began receiving either two
500 mg Mega-RES 99% capsules (made exclusively from
organically grown Japanese knotweed root) or two 500 mg
placebo capsules, twice daily (Candlewood Stars, Danbury,CT).
for 30 days, administered by the nursing staff. Only the research
pharmacist was aware of the study drug allocation. The RES and
placebo capsules were identical, placed in the medication cart
by the pharmacist, and administered to the patients by registered
nurses in identical packaging. Since RES is photosensitive [23],
the product was stored in dark bottles. The measured RES content
of the capsules was 524 mg each so that the total daily dose
administered was actually 2096 mg. Body weight was monitored
each morning in a hospital gown and maintained within 1.5% of
baseline weight by adjusting caloric intake as needed. Subjects
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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consumed an isocaloric, western-style diet, and no other foods
or drinks were permitted. Subjects slept in the hospital where
they always consumed breakfast and dinner and were provided
with a packed lunch on days they did not have testing. On nontesting days, they were permitted to leave the hospital to work or
to pursue other interests. Daily activity was monitored by a New
Lifestyles NL-800 accelerometer (New Lifestyles, Lee’s Summit,
MO). Safety blood laboratory tests and electrocardiogram testing
were monitored. After 30 days of consuming the study drug or
placebo, baseline testing was repeated.
2.3 Procedure methods
2.3.1 Anthropometric measurements
Body weight was measured daily, using a Scale-Tronix 5002 scale
(Welch Allyn, Skaneateles Falls, N.Y.) with a precision of ±0.1 kg.
Subjects were weighed in a hospital gown, after an overnight fast
and post-voiding. Height was measured at baseline with a Seca216 stadiometer (Hamburg, Germany) in 1 mm increments. BMI
was calculated as weight/height squared (kg/m2), using the National
Institutes of Health (NIH) Standard Metric BMI calculator.
2.3.2 Daily blood pressure monitoring
Manual blood pressure readings (Welch Allyn aneroid monitor,
Skaneateles Falls, N.Y.) were taken by the hospital staff each
morning and were recorded. The mean of the systolic and diastolic
readings taken on the four mornings of baseline testing was
statistically compared with the mean of the systolic and diastolic
readings measured on the final 4 days of the study.
2.3.3 REE
On days 7 and 35, REE was determined by indirect calorimetry
using a Viasys Vmax Encore Calorimeter (Cardinal Health, Yorba
Linda, Cal).
2.3.4 2 h oral GTT
On days 6 and 34, a fasting 75 g oral glucose tolerance drink
was administered, and serum glucose and insulin levels were
determined at −10, −5, 0, 30, 60, 90, and 120 min. HOMA-IR
scores were calculated from the 0-time point data: insulin (mU/l)
X glucose (mg/dl).
2.3.5 Abdominal fat biopsy aspiration
On days 7 and 35, subcutaneous abdominal aspiration biopsy
of white adipose tissue was performed under local anesthesia,
using a 4-mm liposuction needle, for gene expression analysis.
2.3.6 Euglycemic hyperinsulinemic clamp
On days 4 and 32, euglycemic-hyperinsulinemic clamp
was performed infusing 80 mU/m2/min Humulin R (Lilly,
Indianapolis, IN). Glucose levels were monitored every 5 min
using the YSI 2300 STAT Plus Glucose and Lactate Analyzer
(Yellow Springs, OH.). Plasma glucose was maintained between
Distributed under creative commons license 4.0

90 and 100 mg/dl by titration of intravenous 20% dextrose solution
(Baxter Healthcare, Deerfield, Ill.) infusion.
2.3.7 Fecal microbiome analysis
Fresh fecal samples were obtained in the hospital, from seven
placebo-treated and nine RES-treated subjects, and samples were
kept frozen at −80°C until analysis. Permission to study fecal
samples in the remaining subjects could not be obtained.
Fecal DNA was extracted from 20 mg aliquots of feces using
the PowerSoil DNA Isolation Kit (QIAGEN, Germantown,
MD) according to the manufacturer’s protocol. Purified DNA
from stool samples was amplified by PCR using the 16S rRNA
V4-region primers (515F/806R) according to the Earth
Microbiome Protocol. Amplified DNA samples were quantified
using the PicoGreen Kit (Qiagen) and were pooled at
equimolar ratios. Samples were then purified by PCR
purification kit (Qiagen). Samples were multiplexed with
unique barcodes and sequenced with 150-bp paired-end reads
(2 × 150) on the MiSeq 2500 platform.
2.3.8 Qiime analysis
The forward and reverse paired-end reads were joined using
the fastq-join command from EA-utils, a command-line tool for
processing biological sequencing data. Reads with a minimum
overlap of 30 nucleotides (nt) and with perfect matching of bases
between reads were demultiplexed and analyzed by quantitative
insights into microbial ecology software (Qiime 1.9.1). Reads
were filtered for base pairs with Phred score >20. The Phred
score is a measure for base quality in DNA sequencing. The
larger the Phred value, the better the quality of a sequenced
base. The sequences were then clustered into operational
taxonomic units (OTUs) using an open-reference approach with
UCLUST, a high-performance clustering alignment and search
algorithm capable of handling millions of sequences. These
sequences were then referenced against the Greengenes 16S
rRNA database (13_8 release), using Python Nearest
Alignment Space Termination (PyNAST) tool. Analysis of
variance (ANOVA) tests of OTU and genus-level abundances
were performed in Qiime. A rarefaction analysis was
accomplished using Chao-1 to estimate diversity (rare OTUs)
from a b u n d a n c e data. Whole phylogenetic diversity (PD)
was performed to measure alpha diversity. Unweighted
UniFrac distances determined by the presence or absence of the
species were calculated to assess beta diversity. The
unweighted pair group method with arithmetic mean was
performed
for UniFrac-based
jackknifed
hierarchical
clustering. Principal coordinate analysis was performed by
calculating UniFrac distance matrices, and KiNG was
used for graphical representation. Linear discriminant analysis
effect size (LEfSe), a tool that can compare differences of relative
abundance between two or more biological conditions, was used
for analysis of the results [24]. Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States
(PICRUSt) was used to predict the metagenomic content from
the 16S rRNA sequencing data, and KEGG (Kyoto Encyclopedia
of Genes and Genomes) pathway functions were categorized at
level 3 [25].
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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2.3.9 Plasma RES and its primary metabolite dihydroresveratrol
(DHR) levels
These were determined in the laboratory of DSM Nutritional
Products Limited, Kaiseraugst, Switzerland, before and after
30 days of RES administration. To determine free RES, an internal
standard (RES-phenyl-13C6) was added to an aliquot of plasma
followed by a liquid-liquid extraction. For conjugated RES forms, a
digestion with β-glucuronidase was performed after addition of an
internal standard, followed by liquid-liquid extraction. After
centrifugation, an aliquot of the organic phase was evaporated to
dryness, redissolved in injection solvent, and analyzed. Quantitation
was achieved by the use of internal standards and an external
standard calibration curve. Samples were analyzed by LC-MS/MS
in negative electrospray mode and validated according to the
bioanalytical method EMEA and FDA validation guidelines.
2.3.10 Analysis of mega-RES 500 mg capsule
After extraction, RES was analyzed by RP-HPLC-UV applying
an isocratic method with a phosphate buffer as mobile phase and
the detection wavelength of 305 nm. Quantification was carried
out using trans-RES as external standard, by a validated method.
2.3.11 RNA sequencing of abdominal white adipose tissue
Abdominal subcutaneous adipose tissue biopsies were analyzed
by RNA SeQ. Total RNA was extracted from approximately 0.5 g
of frozen adipose tissue using a Qiagen RNeasy Lipid Tissue
Mini Kit (Germantown, MD). RNA quality was assessed using
an Agilent Bioanalyzer. Approximately 2–3 mg of RNA with
RNA integrity number 0.7 was submitted. Twenty-one subjects
consented to RNA sequencing of the adipose tissue, six did not
give consent for analysis, and one subject did not undergo the
biopsy due to anxiety. Adipose tissue from before and after
treatment from 10 RES-treated and 11 placebo-treated subjects
was referred for 50-bp paired-end readRNA sequencing polyAenriched RNA at The Rockefeller University Genomics Research
Center. Of those on RES, five were Caucasians and five were nonCaucasians. Gene expression was analyzed for pathway
enrichment using Gene Set Enrichment Analysis (GSEA, Broad
Institute, Cambridge MA) and Ingenuity Pathway Analysis
(Qiagen).
The FASTQ files were first quality controlled through FastOC
v0.11.15 [26]. Cutadapt v1.9.1 was used to locate and remove
the adapter sequences from each high-throughput sequencing
reads before mapping [27], as applied to trim the low-quality
bases and TrueSeq adapters (times =2; quality base =33; quality
cutoff =5; format =FASQT; and minimum length =25 –a
AAAAAAAAAAAAA TTTTTTTTTTTTT –a AGATCGGAAGAG –
a CTCTTCCGATCT). Trimmed FASTQ files were aligned to the
human genome (GRCH37) using STAR v.2.4.2 [28] aligner with
default parameters. The alignment results were then evaluated
through Qualimap v.2.2 [29], to ensure that all the samples had a
consistent coverage, alignment rate, and no obvious 5’ or 3’ bias.
Aligned reads were then summarized through feature Counts v1.5
[30]. The Ensembl gene annotation system, a web-based browser for
vertebral genomes, was used for this purpose. The uniquely mapped
Distributed under creative commons license 4.0

reads (NH “tag” in bam file) that overlapped with an exon (feature)
by at least 1 bp were counted, and then, the counts of all exons
annotated to an Ensembl gene (meta-features) and were summed
into a single number. Empirical analysis of digital gene expression
(edgeR*)v.3.16.5 [31] was used to normalize the samples, and Voom
(mean-variance modeling) from limma # v.3.30.11 was applied to
estimate the differential log fold change in the expression of genes.
2.3.12 Adipose tissue pathway enrichment analysis
A linear mixed-effect model as implemented in R limma package
was applied to analyze differences in gene expressions from pre- to
post-treatment. Moderated t-statistics were used for testing hypotheses
about differential expression. The genes were ranked according to the
magnitude of their significance, determined by the false discovery rate
(FDR), p < 0.05. The ranked gene list was submitted to enrichment
analysis in the GSEA software. The normalized enriched scores
were tested for statistical significance and the gene sets with FDR
< 0.05 were reported as significantly associated with changes from
pre- to post-RES administration. This same procedure was used for a
subgroup analysis that included only Caucasians.

3. Statistical Analysis
In this double-blind pilot randomized parallel group design
placebo-controlled study, the one-sided hypothesis was that RES
reduces insulin resistance in obese, weight-stable men with the
MetS. The primary outcome was the euglycemic hyperinsulinemic
clamp measured at day 30 of the study. Secondary outcomes
included insulin resistance (GTT), systolic and diastolic BP,
triglycerides, circulating inflammatory markers in serum and
adipose tissue, and gene expression in adipose tissue measured at
the same time points as primary outcome. In addition, the effects of
RES on fecal microbiota composition and imputed metagenomic
functions were determined.
3.1 Data protection and management
Unblinded, coded data were downloaded from a secure server,
exported from REDCap to csv. format, and imported into IBM
SPSS 19. Coded data and associated syntax and output files were
maintained on a secure double-password protected desktop.
Transfer of coded data was behind an institutional firewall through
encrypted email. Less than 1% of data was found to be missing so
that subsequent analyses proceeded.
3.2 Power analysis and sample size
Based on preliminary data from prior, unpublished studies, when
randomization results in equivalent distribution of confounders
across groups, the low variability of clamp results suggests extremely
small sample sizes through the use of traditional power calculations.
If one creates 14 matched pairs based on known risk factors, the
risk of at least 10 of the more insulin-resistant subjects being in
one group and at most five of the more insulin-resistant subjects
in the other group (i.e., a 2:1 confounder ratio, or worse) is below
20% and the risk for a 1:5 ratio is below 5%. However, if there is
more than one confounder and the confounders are at least partially
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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Table 1: Baseline metabolic syndrome characteristics of subjects
Clinical Measurement

Placebo (n=14)

Resveratrol (n=14)

p

Mean±SD

CI 95%

Mean±SD

CI 95%

FBG (mg/dl)

104±22

92.–117

98±12

91–105

0.322

HDL (mg/dl)

42±9

37–47

40±7

36–44

0.672

TG (mg/dl)

146±6

114–179

125±75

82–168

0.409

SBP (mmHg)

119±9

115–124

118±6

115–121

0.717

DBP (mmHg)

77±6

74–81

78±2

77–80

0.457

Waist circ (cm)

116±8

111–120

117±11

111–123

0.813

Comparison of the baseline metabolic syndrome characteristics of the total group of resveratrol and placebo treated subjects. mg/dl: Milligrams per deciliter, FBG: Fasting blood glucose,
HDL: High density lipids, TG: Triglycerides, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, mmHg: Millimeters of mercury, cm: Centimeter, waist circ: Waist circumference,
SD: Standard deviation, CI: Confidence interval.

Table 2: Baseline comparison of subjects by treatment
Clinical Measurement

Placebo (n=14)

Resveratrol (n=14)

p

Mean±SD

CI 95%

Mean±SD

CI 95%

4.3±0.9

3.8–4.8

4.4±1.3

3.7–5.2

14+/8

9–19

22±20

10–33

0.194

HOMA (%)

3.7±2.3

2.3–5.0

5.5±6.3

1.8–9.1

0.322

120 min data 2 h GTT (mg/dl)

0.081

Clamp M (mg/kg/min)
Insulin (mlU/L)

0.705

184±58

151–218

153±24

139–167

AUC (mg/dl)

345±77

301–389

310±41

286–333

0.145

WBC (k/mcl)

6.0±1.4

5.2–6.8

6.0±1.6

5.1–6.9

0.960

CRP (mg/dl)

0.33±0.17

0.24–0.43

0.58±0.34

0.39–0.78

0.734

REE (k/cal/day)

1778±204

1652–1898

1754±209

1627–1880

0.789

BMI (kg/m2)

33.8±3.3

32.0–35.7

35.0±3.0

33.2–36.7

0.317

Age (years)

47±8

42–52

48±9

43–60

0.772

Comparison of the baseline laboratory data, BMI and age of the total group of resveratrol and placebo treated subjects. Clamp M: mg/kg/min of dextrose required to maintain plasma glucose
at level of 90–100 mg/dl during euglycemic hyperinsulinemic clamp; 120 min data: The blood glucose level at 120 min of a 2 h oral glucose tolerance test, GTT: Oral glucose tolerance test,
AUC: Area under the curve, HOMA: Homeostatic model assessment, assesses insulin resistance and beta cell function, WBC: White blood cell count, CRP: C‑reactive protein, TG: Serum
triglycerides, REE: Resting energy expenditure, BMI: Body mass index, SD: Standard deviation, CI: Confidence interval.

independent, the resultant ratio may be less. Given the accuracy of
the clamps and the exploratory nature of this study, a sample size
of 14 subjects in each group provides balance for the comparison
of study outcomes. Potential confounders and baseline data were
found not to be significantly different between groups (Table 2).
Randomization, therefore, resulted in homogeneous groups.
3.3 Comparison of effects of the treatment groups on primary
and secondary outcomes
The effects of the intervention on the primary and secondary
outcomes were compared. The primary outcome of the analysis,
the clamp data after 30 days, was compared between the two
groups using a Wilcoxon/Mann–Whitney test. The remaining
outcomes were tested for normal distribution within the groups,
and independent sample two-tailed t-tests were conducted to test
hypotheses that RES had a positive effect (i.e., reduction) on the
primary and secondary outcomes.
3.4 Comparison within subjects of primary and secondary
outcomes
Individual baseline data on the primary and secondary
outcomes had been collected on all subjects allowing for estimates
of changes from pre- to post-treatment within subjects, in addition
to between the two treatment groups, on all outcome variables.
Distributed under creative commons license 4.0

Change scores were calculated for each subject on primary and
secondary variables, using general linear models. Specifically,
analyses of covariance (ANCOVA) were conducted on outcomes
with premeasures of the same variable (e.g., baseline GTT
120 min time point, baseline clamp, and baseline mean systolic
blood pressure). Group assignment was a fixed factor within the
model.
3.5 Comparison of demographics on primary and secondary
outcomes based on post-intervention outcomes
To examine the large within-group subject variance, individual
patient trajectories were graphed over time. Subpatient populations
were constructed blocked on race, ethnicity, and age. The means
and variance for each subgroup were plotted and compared
between groups for significance.

4. Results
4.1 Metabolic components
Of 61 subjects screened, 31 were found eligible and were
entered into the study. Three subjects were withdrawn so that 28
subjects completed the study and 14 subjects were randomized
to each group (Figure 1). The RES preparation was tolerated
well, and measures of plasma RES levels demonstrated that RES
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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subjects were compliant. At baseline, characteristic features of the
MetS did not differ between the RES and placebo-treated groups
(Table 1). Study subjects were all class 1-2 obese with similar
ages and REE (Table 2). There was no evidence of any increase in
inflammatory markers such as white blood count (WBC) and high
sensitivity C-reactive protein (hsCRP).
Following 30 days of RES treatment, there were no significant
differences in the measures that characterized the MetS between
the RES and placebo-treated groups (Table 3A). The insulin clamp
measure of insulin resistance did not differ between the RES
and placebo treated nor did serum insulin and HOMA measures
(Table 3B). However, the 120-min glucose concentration in the
RES-treated subjects was significantly lower than in placebo
subjects (p = 0.023), and the area under the curve for glucose
levels during the GTT was marginally lower (p = 0.05). No other
end point measures differed between the groups. With a priori
significance level of 5%, differences between groups reached
statistical significance on multiple outcomes when mean values
were compared between groups (Table 4).
In a post hoc ANCOVA to control for baseline data (Table 4A),
we observed a difference between the treatment groups (RES vs.
placebo) when divided into Caucasian and non-Caucasian subjects,
in the effects of RES on glucose homeostasis and race. As shown in
Table 4B, there were highly significant effects on insulin resistance
as measured by the insulin clamp technique in Caucasian when
compared to non-Caucasian subjects (p < 0.001). Furthermore, the

120-min end point glucose level and the glucose concentration area
under the curve during the GTT were significantly lower in Caucasian
subjects (Table 4B). At baseline, these two groups did not differ in
age, BMI, or the number of components of the MetS (Table 5).
Since these group differences in glucose homeostasis could
have resulted from differences in RES absorption, distribution, or
metabolism, we measured fasting level of RES and its primary
metabolite, DHR, in all study subjects. The overall data in the
total of 14 RES treated subjects varied greatly between subjects
(Table 6). There were no differences between Caucasian and
non-Caucasian subjects in plasma concentrations of RES and
DHR. We also determined potential correlations between plasma
concentrations of RES and DHR and the MetS components,
adipose tissue gene expression, and fecal microbiota and found no
significant correlations (data were not shown).
4.2 Adipose tissue
To determine changes with RES treatment that may influence
glucose metabolism, abdominal subcutaneous adipose tissue
biopsies were analyzed by RNA SeQ and GSEA enrichment
analysis. After correction for multiple comparisons, no significant
changes in individual gene expression and gene expression
pathways between biopsies taken before and after the study in
placebo-treated subjects were detected. Correcting for multiple
comparisons, there also were no significant differences between
RES and placebo-treated subjects at the end of the study.

Table 3A: Posttreatment comparison of metabolic syndrome characteristics of resveratrol and placebo treated subjects
Clinical Measurement

Placebo (n=14)

Resveratrol (n=14)

p

Mean±SD

CI 95%

Mean±SD

CI 95%

FBG (mg/dl)

104±16

95–113

98±11

91.2–104

0.288

HDL (mg/dl)

41±8

37–46

40±8

36–45

0.664

TG (mg/dl)

130±50

101–159

138±86

86–188

0.762

SBP (mmHg)

120±13

113–128

123±13

116–131

0.476

DBP (mmHg)

79±6

75–82

81±5

78–84

0.207

Waist circ (cm)

115±9

110–121

116±10.4

110–122

0.860

FBG: Fasting blood glucose, HDL: High density lipids, TG: Triglycerides, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, SD: Standard deviation, CI: Confidence interval.

Table 3B: Posttreatment comparison of resveratrol and placebo treated subjects
Clinical Measurement

Placebo (n=14)

Clamp M (mg/kg/min)
Insulin (mg/dl)

Resveratrol (n=14)

p

Mean±SD

CI 95%

Mean±SD

CI 95%

4.2±1.4

3.4–5.0

4.6±1.8

3.6–5.6

0.525

17±8

13–21

20±16

10–29

0.537

HOMA (%)

4.4±2.2

3.1–5.7

5.0±5.2

2.0–7.0

0.698

120 min data 2 h GTT (mg/dl)

172±39

150–195

139±13

120–158

0 0.023*

AUC (mg/dl)

346±64

309–383

304±42

280–328

0.050*

WBC (k/mcl)

5.9±1.3

5.1–6.7

5.2±1.5

4.3–6.1

0.209

CRP (mg/dl)

0.40±0.20

0 0.28–0.52

0.60±0.41

0.36–0.84

0.111

REE (k/cal/d)

1798±225

1662–1934

1778±228

1640–1976

0.821

BMI (kg/m2)

33.7±3.3

31.8–35.6

34.9±3.0

33.2–36.7

0.331

Comparison of the posttreatment metabolic syndrome characteristics (3A) and laboratory data and BMI (3B) for the total group of resveratrol and placebo treated subjects. *P≤ 0.05.
GTT: Oral glucose tolerance test, AUC: Area under the curve, HOMA: Homeostatic model assessment, assesses insulin resistance and beta cell function, WBC: White blood cell count,
CRP: C‑reactive protein, TG: Serum triglycerides, REE: Resting energy expenditure, BMI:Body mass index, SD: Standard deviation, CI: Confidence interval.
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Table 4A: Baseline comparison of significant findings by subject race
Clinical Measurement

Non-Caucasians (n=17)

Caucasians (n=11)
Mean±SD

CI 95%

Mean±SD

p

CI 95%

Clamp M

3.9±1.1

3.2‑4.7

4.6±1.1

4.1‑5.2

0.090

120 min data 2 h GTT (mg/dl)

154±26

137‑171

178±55

150‑206

0.192

AUC (mg/dl)

318±33

295‑340

334±77

294‑373

0.518

GTT: Oral glucose tolerance test, AUC: Area under the curve, SD: Standard deviation, CI: Confidence interval.

Table 4B: Posttreatment comparison of significant findings by race within treatment groups
Placebo (n=14)

Clinical Measurement

Mean±SD

Resveratrol (n=14)
CI 95%

Mean±SD

Caucasians (n=6)

p
CI 95%

Caucasians (n=5)

Clamp M

4.3±1.5

2.7–5.9

4.9±2.5

1.7–8.0

<0.001*

120 min data 2 h GTT (mg/dl)

163±26

136–191

132±24

102–162

0.001*

350±55

293–408

302±29

266–339

0.006*

AUC (mg/dl)

Non-Caucasians (n=8)

Non-Caucasians (n=9)

Clamp M

4.2±1.5

3.0–5.4

4.5±1.4

120 min data 2 hGTT (mg/dl)

179±47

140–218

344±75

281–405

AUC (mg/dl)

3.4–5.5

0.940

143±38

114–173

0.962

305±49

267–343

0.376

Comparison of the baseline (4A) and posttreatment (4B) glucose tolerance and clamp M data in the Caucasian and noncaucasian group of resveratrol and placebo treated subjects. GTT: Oral
glucose tolerance test, AUC: Area under the curve, SD: Standard deviation, CI: Confidence interval.

Table 5: Baseline comparison by race in resveratrol treated subjects (n=14)
Clinical Measurement
FBG (mg/dl)
HDL (mg/dl)

Non-Caucasians (n=9)

Caucasians (n=5)

p

Mean±SD

CI 95%

Mean±SD

CI 95%

95±10

83.0–107

102±16

90–114

0.366

37±3

33–40

41±6

37–46

0.136

177±100

52–301

101±38

72–130

0.170

SBP (mmHg)

117±5

110–123

119±6

114–124

0.415

DBP (mmHg)

78±3

74–82

80±2

78–81

0.233
0.258

TG (mg/dl)

Waist circ (cm)

121±12

108–135

115±10

107–122

BMI (kg/m2)

34.1±2.8

30.6–37.6

35.6±2.9

33.3–37.8

0.375

Age (years)

49±9

38–59

47±9

41–54

0.785

Comparison of the baseline characteristics and laboratory data of the caucasian and noncaucasian resveratrol treated subjects. FBG: Fasting blood glucose, HDL: High density lipids,
TG: Triglycerides, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, SD: Standard deviation, CI: Confidence interval, BMI: Body mass index.

Table 6: Plasma resveratrol and dihydroresveratrol levels post resveratrol treatment (n=14)
Components

Mean±SD

p

Caucasians (n=5)

Non-Caucasians (n=9)

RES (nmol/L)

23,203±8,467

27,349±13,908

0.559

DHR (nmol/L)

2,276±3,411

5,709±10,111

0.482

Terms: RES nmol/L: Resveratrol measured in nano‑moles/liter. DHR nmol/L: Dihydroresveratrol, the primary metabolite of resveratrol, measured in nano‑moles/liter. RES: Resveratrol,
DHR: Dihydroresveratrol, SD: Standard deviation.

To gain further insight into possible effects of RES intervention
on adipose tissue gene expression for subsequent, more detailed
study, we evaluated a selection of the top individual genes that
were altered in the RES intervention group of subjects (Table 7).
Upregulated gene expression occurred with the RAB 40A member
of the RAS oncogene family, microRNA 192, apolipoprotein C4,
Distributed under creative commons license 4.0

a growth differentiation factor, a member of the TNF 2 receptor
superfamily, the 5-hydroxytryptamine receptor1B, two olfactory
receptors, and 32 long, intergenic non-protein coding RNAs. We
found no significantly downregulated genes by RES treatment.
Contrary to expectations, genes related to SIRT1 and mTOR
pathways did not change.
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By GSEA analysis, the three Caucasian subjects were negatively
enriched with the TGF beta signaling gene expression pathway
compared to the five non-Caucasians from whom adipose tissues
were available for analysis.
4.3 Comparison of intestinal bacterial communities in the
placebo and RES treatment groups
Fecal samples were available for the study from seven Caucasian
and nine non-Caucasian subjects. Nine subjects (3 Caucasians and
6 non-Caucasians) received RES. In these subjects, both alphadiversity as measured by PD and community structure as measured

by beta diversity changed significantly over the course of the
study, but as expected, no significant differences developed in the
placebo-treated controls (Figure 2). The community structure did
not differ significantly pre-treatment between the two groups but
differed post-treatment (p = 0.01). The data showed that species
richness (alpha-diversity, as measured by PD) fell over the course
of the study in the total of 16 subjects in whom specimens were
available but had no significant differences in the community
structure (beta differences as measured by UniFrac distances).
Next, we asked whether individual taxa showed significant
changes in relative abundance in the RES and the placebo groups

Table 7: Postresveratrol selection of altered genes in subcutaneous adipose tissue
Gene symbol

Gene designation

RAB40A

RAB40A member RAS oncogene family

0.00013

p

Log fold change
0.2715

FAM230C

Family with sequence similarity 230 member C

0.00026

0.2330

MIR192

micro‑RNA 192

0.0012

0.2117

APOC4

Apolipoprotein C

0.0014

0.1934

MFAP2

Microfibrillar associated protein 2

0.0019

0.2434

GDF2

Growth differentiation factor 2

0.0027

0.2564

OR52E4

Olfactory receptor family 52, subfamily E, member 4

0.0031

0.1918

OR4D6

Olfactory family 4, subfamily D, member 6

0.0033

0.1820

TNFRSF13B

TNF receptor superfamily member 13B

0.0036

0.2052

HTR1B

5‑hydroxytryptamine receptor 1B

0.004

0.2128

LINC00982

Long intergenic non‑protein coding RNA 982

0.005

0.5994

LINC01356

Long intergenic non‑protein coding RNA 1356

0.005

0.5141

Significantly altered gene expression data in adipose tissue following resveratrol treatment.

Figure 2: Differences in fecal microbiota between the resveratrol (RES) and placebo-control total subject groups. Upper panels: β-diversity as
determined by unweighted UniFrac analysis; Lower panels: Differences in α-diversity between groups, left, mean ± standard deviation; right, Median
+ interquartile range box and whisker (95%) confidence interval. Plot color codes: Blue: Placebo-control pre-treatment; Red: Placebo-control posttreatment; Green: RES pre-treatment; Light blue: RES post-treatment. In RES-treated subjects, significant changes were seen in alpha-diversity, as
measured by phylogenetic diversity (p = 0.01), and community structure, as measured by beta diversity (p = 0.007). There were no changes in the
placebo group pre- and post-treatment.
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(Figure 3). In placebo controls, there were no significant differences in
the taxa comparing the pre- and post-treatment specimens. However,
several taxa changed significantly in the RES subjects with a fall in
Rikenellaceae, Ruminococcus, Oscillospira, Clostridium, Alistipes,
Odoribacter, and Butyricimonas and a rise in Gammaproteobacteria,
Gemellaceae, Turicibacter, and Atopobium.
In the PICRUSt comparative analysis of imputed biochemical
pathways in the metagenome (Figure 4), placebo-treated subjects
again showed no significant differences, whereas the RES group
showed decreases in pathways related to ribosomal translation,
aminoacyl tRNA biosynthesis, apoptosis, carotenoid biosynthesis,
and cysteine and methionine metabolism. Post-RES treatment, the
dominant pathways were glutathione metabolism, ion transport
and metabolism, pertussis, biotin metabolism, and fatty acid
metabolism.
Since we found several differences in glucose tolerance and
insulin resistance between the Caucasian and non-Caucasian
RES-treated subjects, we examined changes in fecal microbiota
corresponding to these individuals. There were no significant
differences in either alpha or beta diversity between Caucasian
and non-Caucasian subjects (data are not shown). However,
LefSe showed significant taxonomic differences between
these two groups. In the Caucasians, Alistipes, Collinsella,
Christensenella, Holdemania, and Turicibacter were among
the taxa that fell during the treatment and Bilophila rose
(Appendix
Figure
F1).
In
non-Caucasians,
Ruminococcaceae,
Alphaproteobacteria,
Christensenella,
Odoribacter, and Clostridium were taxa that fell

during treatment, while Proteobacteria rose (Appendix Figure F2.).
In pre-study Caucasians, there was significant over-representation of
Collinsella, Clostridiaceae, and Ruminococcus, but Streptococcus
and Lactobacillales were overrepresented in the non-Caucasians
(Appendix Figure F3). Post-treatment, the Caucasian subjects
showed significantly higher levels of Akkermansia muciniphila,
Fusobacteria, and Megamonas, compared to the non-Caucasians
(Appendix Figure F4).

5. Discussion
This double-blind, placebo-controlled study of a large dose of
RES (2 g daily) did not show a significant effect on insulin sensitivity
or glucose homeostasis, by our primary endpoint of euglycemic
hyperinsulinemic clamp, when compared to the placebo-treated
group of subjects. Glucose homeostasis was marginally affected as
measured by GTT. The placebo and RES groups did not differ in
factors contributing to the MetS or other potentially important end
point variables. Our essentially inconclusive results agree with a
5-week cross-over study of RES 1 g/day in diet-controlled diabetic
subjects [32]. Furthermore, this is consistent with a placebocontrolled study of RES 150 mg or 1 g/day in moderately obese but
otherwise healthy community-living men [33], as well as a study
by Poulsen et al. [34], which used RES 1.5 g/day in obese subjects
and failed to improve insulin resistance.
These studies were in contrast with earlier studies in which
RES 1–2 g/day was provided to older subjects with impaired
glucose tolerance who showed modest improvement in insulin

Figure 3: LefSe Cladogram and left anterior descending score of treatment differences. Identification of significant taxonomic differences
associated with the total placebo-control group (n = 14 samples) and of the total resveratrol (RES) group (red: Pre-treatment, green: Post-treatment)
(n = 18 samples). (Right) histogram of the linear discriminant analysis scores was calculated for the most differential taxa with RES treatment.
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Figure 4: Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PIECRUSt) functional analysis of the control
(placebo) and resveratrol (RES) treatments in the total subject group. Analyses using functions imputed by the PICRUSt algorithm, with score of linear
discriminant analysis [LDA] >2. Histogram of the LDA scores was calculated for the most abundant taxa altered by the RES treatment.

resistance estimated from the Matsuda index [11] and a 3-month
open-label study of RES 250 mg/day in patients with type
2 diabetes taking oral antidiabetic medications [35]. Crandall, in
an editorial, wondered whether RES would be effective only
when glucose homeostasis was clinically impaired [36].
Korshalm et al. [37] agreed that subjects with modest insulin
resistance are optimal to measure effects of RES on insulin
resistance, but that healthy individuals with normal glucose
homeostasis might not be affected by RES. In addition, longer
studies may be necessary to determine the effect of RES on
chronic conditions such as insulin resistance and low-grade
inflammation.
It has been stated that there is sufficient information from
rodent studies that RES has the capacity to improve insulin
sensitivity and reduce blood glucose levels accompanied by
modulation of inflammatory response to various stimuli. RES
has been used in conjunction with metformin to improve
insulin sensitivity and glucose homeostasis in pre-diabetic
subjects [38]. However, studies in humans are fragmentary
and generally inadequate [39].
Unexpectedly, when we performed a post-hoc analysis of the
several factors that could have influenced our data, including the
effects of race, the Caucasian subjects showed a highly
significant effect of RES on glucose homeostasis, with reduction
in insulin resistance, and a decline in both the 120-minute
glucose concentration and the area under the curve in the oral
glucose tolerance test, whereas non-Caucasian subjects had no
significant effects on these measures. However, the dispersion of
the non-Caucasian subjects’ 120-minute glucose concentration
Distributed under creative commons license 4.0

and the area under the curve was greater than the Caucasian
subjects, which could decrease the likelihood of significant
finding within the non-Caucasian subjects.
These differences could have reflected variation in RES
absorption, known to be inconsistent [16], or in RES distribution
and metabolism. Our current data on fasting plasma concentration
of RES and its primary metabolite DHR did not explain the
difference in glucose homeostasis with RES administration in the
Caucasian subjects. We recognize that our study was powered for
our primary outcome, a change in insulin resistance, and not for
the secondary outcomes. This poses the potential that a type 2 error
might have occurred in the analysis of the secondary outcomes.
Our data are in contrast with a Dutch comprehensive metabolic
study of 11 grade 1 obese healthy men without MetS and
mean 26% body fat, who were administered RES in a dose of
150 mg/day for 30 days in a placebo-controlled, cross-over
study [40]. These authors reported that RES reduced resting
metabolic rate, muscle inflammation, and intramyocellular lipid
content. The RES-treated group in this study also showed
reductions in fasting serum glucose, triglycerides, leptin,
insulin, and HOMA, as well as several circulating markers of
inflammation. The reasons for the differences between our
results and their data are unclear. It is of interest that the subjects
in the Timmers study were all Caucasians (personal
communication), and thus, their improvement with RES may
have paralleled the data in our Caucasian subjects. The RES
dose of 150 mg/day and the fasting plasma levels of RES and
DHR in the Timmers’ study were much lower than those measured
in our study. Lower concentration effects might reflect an inverted
DOI: http://dx.doi.org/10.18053/jctres.04.201802.004
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U effect. Further studies of RES administration to obese or MetS
Caucasians and non-Caucasian subjects seem warranted.
We included studies of subcutaneous white adipose tissue gene
expression, since adipose tissue dysfunction is common in obese
subjects, and RES might improve inflammation in fat tissues.
Although we found no significant changes in the expression of
genes and gene pathways in adipose tissue after correction for
multiple factors, the selection of the individual genes that were
most upregulated by RES included two olfactory genes. Several
olfactory receptor genes in adipose tissue have been reported to
modulate increased fat mass in obesity [41]. In rodents fed a high
fat controlled diet, RES 30 mg/kg body weight was shown to
reduce body weight, fat mass, and white adipose tissue lipolytic
activity [42]. Others have described downregulation of the mTOR
pathway improving glucose and lipid metabolism in mice [10,20],
and inflammatory markers [19], after RES administration. These
data differ from our null findings in human subcutaneous
adipose tissue. In contrast, in another human study, RES at a
dose of 150 mg/day for 30 days in obese men was reported to
reduce adipocyte size associated with regulation of genes linked
with cell cycle regulation and lysosomal activity, suggesting
stimulation of an alternative pathway of lipid metabolism [43].
The reasons for the discrepancy between the two studies are
unclear, but these data were taken from subjects in the crossover metabolic study by Timmers discussed previously.
Increasing evidence has focused on the role of the gut
microbiota in determining the metabolism of drugs and certain
over-the-counter supplements [44]. Furthermore, drugs and
supplements can alter the composition and the function of the
microbiota in the gut [45]. Although RES has been shown to affect
the gut microbiome in vitro and in rodents in vivo [46], these data
are not consistent across studies. A comprehensive metabolomic
analysis on blood, urine, adipose tissue, and skeletal muscle tissue
in middle-aged men with MetS randomized to receive either RES
or placebo treatment for 4 months found that the composition of
the gut microbiota was altered by RES treatment, with a reduction
in sulfated androgen precursors in blood, adipose tissue, and
muscle, increasing these metabolites in the urine [37].
The microbiome may also affect the metabolism of RES [47].
The principal metabolite is DHR, but further molecular changes
include glucuronidation and sulfation [46], which occur in the
gastrointestinal tract and liver. A detailed in vitro study of the
effects of the gut microbiota on RES showed that the major RES
metabolite resulting from gut microbial action was DHR and
indoxy metabolites, including the formation of lumularin [16].
In the panel of microbes used for these in vitro studies,
Slakia equolifaciens and Adlercreutzia equolifaciens were
the principle producers of DHR. In mice, RES 200mg/kg/day
was shown to improve gut microbial dysbiosis as measured by
increased Lactobacillus and Bifidobacterium species and reduced
Enterococcus faecalis [17]. Lachnospiraceae often produces
butyrate, a beneficial short-chain fatty acid [48]. By inhibition
of several commensal microbiota, RES can attenuate the gut
microbial metabolism of TMAO [18]. Indeed, in TMAO-fed
Apo-E -/- mice, RES inhibited atheroma formation through
Distributed under creative commons license 4.0

changes in such gut microbiota accompanied by increased bile salt
hydrolase deconjugation of conjugated bile salt acids.
In our study, RES reduced microbial diversity and led to
several changes in individual microbiota. RES-treated Caucasian
subjects who showed improvement in insulin sensitivity and
glucose homeostasis also had a significant increase in A.
muciniphila, a microbe that, in experimental animals, has
been inversely associated with obesity, diabetes, and low-grade
inflammation [49]. Administration of a purified A. muciniphila
membrane protein to mice also has improved insulin
sensitivity and reduced fat mass [50], consistent with potential
therapeutic efficacy.
Although other investigators have focused on the role of RES
as a SIRT activator, we found no change in SIRT gene expression
in adipose tissue. SIRT1 has been linked to both lipid and glucose
homeostasis. In white adipose tissue, SIRT1 inhibited
adipogenesis in precursor cells and reduced fat storage in
differentiated cells [51]. SIRT1 can also regulate glucose
homeostasis by altering different tissue targets. In pancreatic βcells, SIRT1 is a positive regulator of insulin secretion and can
protect β-cells against oxidative stress by deacetylation of FOX-0
proteins. In the liver, SIRT1 may regulate gluconeogenesis. In
target tissue, SIRT1 may affect glucose homeostasis by
modifying the responses of target cells to insulin, by regulating
the activity of PGC-1α [52].

Conclusions
We demonstrated only minor overall effects of the
administration of RES in a dose of 2 g/day to obese men with
insulin resistance and the MetS. However, post-hoc analysis
showed a significant improvement in insulin sensitivity and
glucose tolerance during a 2-h oral GTT, in RES-treated
Caucasian subjects. These improvements were not seen in
non-Caucasians treated with RES. This observation was not
explained by differences in RES absorption or metabolism as
determined by measuring plasma concentrations of RES and
its primary metabolite DHR or by examining the effects on
adipose tissue gene expression. In fecal microbiome, RES
altered alpha and beta diversity in treated subjects
compared to placebo control subjects. Further studies of RES
in Caucasian and non-Caucasian insulin resistant, obese
subjects are needed to confirm our finding and to seek functional
explanation for these differences.
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